Abstract P5-06-27: Circulating cancer associated macrophage-like cells (CAMLs) are early predictors of response to new line therapies in metastatic breast cancer

Metastatic Breast ◽

Early Predictors ◽

Predictors Of Response

Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (pts) with locally recurrent or advanced metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1048 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1048-1048 ◽

Cited By ~ 5

Author(s):

S. D. Patterson ◽

M. T. Davis ◽

J. R. Mackey ◽

M. Martin ◽

Y. Hei ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Response To Treatment ◽

Predictors Of Response ◽

Locally Recurrent

Circulating tumor and endothelial cells as predictors of response in metastatic breast cancer

Breast Cancer Research ◽

10.1186/bcr1686 ◽

2007 ◽

Vol 9 (S1) ◽

Author(s):

M Cristofanilli

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Metastatic Breast ◽

Predictors Of Response

A review of the newer aromatase inhibitors in the management of metastatic breast cancer

Journal of Clinical Pharmacy and Therapeutics ◽

10.1046/j.1365-2710.1998.00145.x ◽

1998 ◽

Vol 23 (2) ◽

pp. 81-90 ◽

Cited By ~ 7

Author(s):

Reddy

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitors ◽

Metastatic Breast

Influence of cumulative dose (CD) of trastuzumab administred wit taxanes vs pre-treatment CD of anthracyclin on left ventricular ejection fraction (LVEF) of metastatic breast cancer (MBC) patients

10.1016/s0959-8049(02)80427-0 ◽

2002 ◽

Vol 38 (11) ◽

pp. S131

Author(s):

B Aunoble

Keyword(s):

Breast Cancer ◽

Left Ventricular Ejection Fraction ◽

Ejection Fraction ◽

Cumulative Dose ◽

Metastatic Breast ◽

Left Ventricular ◽

Left Ventricular Ejection ◽

Ventricular Ejection Fraction ◽

Pre Treatment

Gemcitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Evaluation of response toxicity

10.1016/s0959-8049(02)80224-6 ◽

2002 ◽

Vol 38 (11) ◽

pp. S74 ◽

Cited By ~ 2

Author(s):

G Lerzo

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Previously Treated

Safety of Herceptin monotherapy administered on a 3-weekly schedule: Preliminary data from a phase II study in women with HER2-positive metastatic breast cancer

10.1016/s0959-8049(02)80299-4 ◽

2002 ◽

Vol 38 (11) ◽

pp. S95

Author(s):

J Baselga

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Schedule ◽

Her2 Positive

Epirubicin and vinorelbine versus single agent epirubicin as first line chemotherapy in metastatic breast cancer

10.1016/s0959-8049(02)80197-6 ◽

2002 ◽

Vol 38 (11) ◽

pp. S66-S67

Author(s):

B Ejlertsen

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

First Line ◽

Line Chemotherapy

Bevacizumab Approved for Metastatic Breast Cancer

Internal Medicine News ◽

10.1016/s1097-8690(08)70305-6 ◽

2008 ◽

Vol 41 (6) ◽

pp. 1-4

Author(s):

ELIZABETH MECHCATIE

Keyword(s):

Breast Cancer ◽

Metastatic Breast

Abstract #804323: Metastatic Breast Cancer Involving Thyoid Gland Presenting as a Stable 1 CM Nodule with High Risk Features on Ultrasonography

Endocrine Practice ◽

10.1016/s1530-891x(20)39577-x ◽

2020 ◽

Vol 26 ◽

pp. 267-268

Author(s):

Ahmad Al-Shoha

Keyword(s):

Breast Cancer ◽

High Risk ◽

Metastatic Breast

Abstract #42: Pan-hypopituitarism in a Patient with Metastatic Breast Cancer, and Review of Literature Regarding Pituitary Metastasis

Endocrine Practice ◽

10.1016/s1530-891x(20)46321-9 ◽

2004 ◽

Vol 10 ◽

pp. 16

Author(s):

Garumuni A. DeSilva ◽

Rennert ◽

Samuel Engel

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Review Of Literature ◽

Pituitary Metastasis